SIGA Technologies, Inc. (SIGA) Insider Trading Activity

NASDAQ$6.58
Market Cap
$471.2M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
813 of 892
Rank in Industry
45 of 50

SIGA Insider Trading Activity

SIGA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
–
Sells
$0
0
–

Related Transactions

About SIGA Technologies, Inc.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

Insider Activity of SIGA Technologies, Inc.

Over the last 12 months, insiders at SIGA Technologies, Inc. have bought $0 and sold $0 worth of SIGA Technologies, Inc. stock.

On average, over the past 5 years, insiders at SIGA Technologies, Inc. have bought $0 and sold $234,600 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $44,200 was made by Gomez Phillip Louis III () on 2019‑12‑09.

List of Insider Buy and Sell Transactions, SIGA Technologies, Inc.

2021-12-09SaleAntal Jamesdirector
30,000
0.0401%
$7.82
$234,600
+23.68%
2020-08-27SaleAntal James
30,000
0.0385%
$7.10
$213,000
-3.67%
2019-12-09PurchaseGomez Phillip Louis III
10,000
0.0125%
$4.42
$44,200
+35.42%
2019-12-09PurchaseSAVAS PAUL G
20,000
0.0247%
$4.37
$87,400
+35.42%
2019-12-09PurchaseLuckshire Daniel J
5,000
0.0062%
$4.39
$21,950
+35.42%
2019-12-09PurchaseKane Julie
2,500
0.0031%
$4.39
$10,975
+35.42%
2019-08-23PurchaseSAVAS PAUL G
10,000
0.0124%
$4.95
$49,500
+9.14%
2019-08-09PurchaseSAVAS PAUL G
10,000
0.0124%
$5.08
$50,800
+4.31%
2019-06-07SaleHruby Dennis E
16,000
0.0197%
$5.58
$89,280
-6.81%
2019-06-06SaleHruby Dennis E
17,000
0.0212%
$5.57
$94,690
-5.07%
2019-06-05SaleHruby Dennis E
17,000
0.0211%
$5.68
$96,560
-7.02%
2019-06-05SaleAntal James
30,000
0.0374%
$5.70
$171,000
-7.02%
2019-06-04PurchaseBAYER MICHAEL J
12,500
0.0152%
$5.74
$71,750
-9.86%
2018-11-16PurchaseSAVAS PAUL G
5,000
0.0063%
$5.58
$27,900
+0.98%
2018-11-13SaleHruby Dennis E
31,099
0.0384%
$5.29
$164,514
+5.36%
2018-11-12SaleHruby Dennis E
18,901
0.0238%
$4.96
$93,749
+14.40%
2018-11-12PurchaseSAVAS PAUL G
10,000
0.0127%
$5.01
$50,100
+14.40%
2018-11-12PurchaseGomez Phillip Louis III
15,000
0.0198%
$5.20
$78,000
+14.40%
2015-09-24SaleROSE ERIC A MDChief Executive Officer
20,000
0.0359%
$1.21
$24,200
-33.60%
2015-09-01SaleROSE ERIC A MDChief Executive Officer
20,000
0.0368%
$1.32
$26,400
-37.59%
Total: 101

Insider Historical Profitability

12.58%
MacAndrews & Forbes Holdings Inc.
13509722
18.8653%
$88.89M60
<0.0001%
ROSE ERIC A MDChief Executive Officer
582897
0.814%
$3.84M37
+78.43%
KASTEN BERNARD LChief Executive Officer
553559
0.773%
$3.64M10
<0.0001%
Gomez Phillip Louis III
475782
0.6644%
$3.13M20
+24.91%
BURGESS SUSAN K
365783
0.5108%
$2.41M07
SAVAS PAUL G
292847
0.4089%
$1.93M80
+5.44%
Luckshire Daniel J
224943
0.3141%
$1.48M11
+35.42%
CONSTANCE THOMAS Edirector
155000
0.2164%
$1.02M02
Hruby Dennis E
147465
0.2059%
$970,319.70013
BAYER MICHAEL J
132244
0.1847%
$870,165.5233
<0.0001%
Antal Jamesdirector
100875
0.1409%
$663,757.5004
SLOVIN BRUCEdirector
95000
0.1327%
$625,100.0092
+59.85%
Odden JohnVP - Business Development
55240
0.0771%
$363,479.2040
<0.0001%
Bevins William Cdirector
50000
0.0698%
$329,000.0010
+16.22%
Fasman Steven Ldirector
47000
0.0656%
$309,260.0010
+25%
Marshall Joseph W IIIdirector
30000
0.0419%
$197,400.0030
<0.0001%
TRANSTECH PHARMA INC10 percent owner
20983
0.0293%
$138,068.1402
MJALLI ADNAN M M
20983
0.0293%
$138,068.1402
Kane Julie
2500
0.0035%
$16,450.0010
+35.42%
STERN ANDREW Ldirector
2150
0.003%
$14,147.0010
<0.0001%
TOWNSEND FRANCES Fdirector
2000
0.0028%
$13,160.0010
<0.0001%
WEINER MICHAEL MDdirector
0
0%
$0011
PERELMAN RONALD O10 percent owner
1
0%
$6.5820
<0.0001%

Historical Insider Profitability vs. Competitors

$2,058,674
1631
-10.96%
$69.55M
$218,350,131
64
16.68%
$600.49M
$125,860,243
57
-4.48%
$37.72M
$129,489,279
57
26.09%
$481M
$2,767,882
51
8.70%
$27.28M
$102,709,455
46
30.55%
$824.29M
SIGA Technologies, Inc.
(SIGA)
$33,884,330
45
12.58%
$471.2M
$97,642,477
41
-10.58%
$337.06M
$6,021,989
30
-0.17%
$328.7M
$32,539,771
28
33.37%
$177.72M
$6,506,230
27
-16.20%
$968.76M
$25,034,841
20
9.38%
$732.05M
$1,843,996
10
22.92%
$1.2B
$1,718,514
9
38.12%
$957.3M
$758,061
9
60.03%
$184.63M
$208,823
7
-1.10%
$73.66M
$179,515
7
1.51%
$586.33M
$543,932
6
-22.06%
$733.64M
$12,300,713
4
24.14%
$307.97M

SIGA Institutional Investors: Active Positions

Increased Positions106+57.92%4M+11.42%
Decreased Positions74-40.44%4M-12.41%
New Positions37New1MNew
Sold Out Positions16Sold Out918,703Sold Out
Total Postitions215+17.49%34M-0.99%

SIGA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$22,108.004.9%3.53M-101,955-2.81%2025-09-30
Vanguard Group Inc$16,653.003.69%2.66M+142,036+5.65%2025-09-30
Dimensional Fund Advisors Lp$15,251.003.38%2.43M+24,901+1.03%2025-09-30
Altravue Capital, Llc$15,158.003.36%2.42M-83,630-3.34%2025-09-30
American Century Companies Inc$7,729.001.71%1.23M-172,442-12.27%2025-09-30
Citadel Advisors Llc$7,055.001.56%1.13M-269,332-19.31%2025-09-30
State Street Corp$6,482.001.44%1.03M-76,163-6.86%2025-09-30
Geode Capital Management, Llc$6,259.001.39%998,222+274+0.03%2025-09-30
Jupiter Asset Management Ltd$6,211.001.38%990,64800%2025-09-30
Arrowstreet Capital, Limited Partnership$5,233.001.16%834,683+255,902+44.21%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.